Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

October 31, 2015

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Gefitinib

Gefitinib 250mg/d every cycle d15-25,and Gefitinib 250mg/d from d15 of last cycle until disease progression

DRUG

Gemcitabine +Carboplatin

Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles

Trial Locations (1)

200030

Shanghai Lung Tumor Clinical Center,Shanghai Chest Hospital, Shanghai

All Listed Sponsors
collaborator

The First Hospital of Jilin University

OTHER

collaborator

Ruijin Hospital

OTHER

collaborator

Fudan University

OTHER

collaborator

Jiangsu Cancer Institute & Hospital

OTHER

collaborator

Nanjing PLA General Hospital

OTHER

collaborator

Wuxi No. 4 People's Hospital

OTHER

collaborator

The First Affiliated Hospital of Soochow University

OTHER

collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

collaborator

Sir Run Run Shaw Hospital

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Changhai Hospital

OTHER

collaborator

NanJing PLA 81 Hospital

OTHER

collaborator

First People's Hospital of Hangzhou

OTHER

lead

Guangdong Association of Clinical Trials

OTHER

NCT01404260 - Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter